|
Rapamycin
|
Impair
|
Prohibiting TGF-β-induced EMT
|
Gallbladder cancer (GBC)
|
[27]
|
|
Rapamycin
|
Impair
|
Inhibiting depletion of FBXW7-induced EMT and stem cell-like behavior
|
Colon cancer
|
[146]
|
|
Rapamycin
|
Impair
|
Prohibiting TGF-β-induced EMT
|
A cell culture model of TGF-β-induced EMT
|
[147]
|
|
Brusatol
|
Impair
|
Decreasing expression of N-cadherin, Vimentin and up-regulating expression of E-cadherin
|
Hepatocellular carcinoma (HCC)
|
[148]
|
|
Combination of P38 inhibitor SB202190 and JUN inhibitor SP600125
|
Impair
|
Inhibiting EMT markers expression
|
Ovarian cancer
|
[149]
|
|
Alisertib (ALS, MLN8237)
|
Impair
|
Regulating E-cadherin suppressor with the involvement of Sirt1
|
Osteosarcoma (OS)
|
[150]
|
|
mTORC inhibitor AZD2014
|
Impair
|
Down-regulating the expression of Snail and MMP2
|
Hepatocellular carcinoma (HCC)
|
[151]
|
|
Metformin
|
Impair
|
Inhibit mTOR pathway and regulate expression of the EMT-related markers E-cadherin, N-cadherin, and Snail.
|
Thyroid cancer
|
[28]
|
